Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

The attrition rate for anticancer drugs entering clinical trials is unacceptably high. For multiple myeloma (MM), we postulate that this is because of preclinical models that overemphasize the antiproliferative activity of drugs, and clinical trials performed in refractory end-stage patients. We val...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Chesi, Marta, Matthews, Geoffrey M., Garbitt, Victoria M., Palmer, Stephen E., Shortt, Jake, Lefebure, Marcus, Stewart, A. Keith, Johnstone, Ricky W., Bergsagel, P. Leif
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2012
Teme:
Lymphoid Neoplasia
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3398763/
https://ncbi.nlm.nih.gov/pubmed/22451422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-02-412783
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki